Hims & Hers Health stock forecast: Downside momentum likely to persist near $16.91 support
Hims & Hers Health (HIMS) stock is trading at $18.56 after a decline of 5.98% for the day, moving sharply lower and closing near session lows. The price remains below its key moving averages across all observed timeframes, reflecting continued downward momentum.
Highlights
- Hims & Hers Health reported third-quarter revenue of $890.4 million, representing a 49% increase year-over-year.
- The company posted a net loss of $33 million and lower gross margin at 57%, and it plans to broaden its weight-loss drug lineup with new products from Lilly, Foundayo, and Novo Nordisk when available.
- Shares of Hims & Hers Health trade below key moving averages with a prevailing downtrend and high volatility, forecast range $16.91 to $20.21, and a 78% probability of further downside.
Profitability concerns grow despite strong revenue gains and product expansion
Hims & Hers Health reported third-quarter revenue of $890.4 million, marking a 49% increase year-over-year and reflecting substantial growth in business volume, according to TradingView. However, the quarter was accompanied by a net loss of $33 million and a decline in gross margin to 57%, underscoring ongoing pressures on profitability and cost structure. The company also announced an expansion to its weight-loss drug lineup, outlining plans to add new products from Lilly, Foundayo, and Novo Nordisk when available, which may support future growth opportunities though price action has remained under broader selling pressure.
Downside bias prevails amid oversold conditions and resistance barriers
On the technical front, HIMS/USD remains below the H1 SMA-20 at $19.51, H1 SMA-50 at $21.09, and D1 SMA-200 at $26.63, with the Ichimoku Kijun at $19.67 acting as immediate resistance to any upward moves. MACD and ADX are both confirming downside momentum, while RSI stands neutral. Stoch RSI and CCI are deep in oversold territory, which can indicate selling exhaustion, and Bull/Bear Power is negative at -0.49, suggesting sellers maintain control. The Awesome Oscillator provides no clear bias. This mix of momentum and oscillator readings highlights a prevailing downward bias with some potential for short-lived rebounds if selling subsides.
Greater downside risk seen as consolidation signals likely volatility
Looking ahead over the next several sessions, HIMS is likely to consolidate within a typical volatility band between $16.91 and $20.21. Downside is more probable, with a 78% likelihood of a move lower and just 22% for an upward reversal attempt. Should price break and close above resistance at $19.67, a short-term recovery could develop. Conversely, a decisive move below $16.91 risks accelerating bearish momentum and extending the drawdown.
Earlier, analysts noted that Hims & Hers Health shares faced persistent downside risk and bearish technical momentum. The latest technical developments and corporate updates reinforce this view, highlighting the importance of monitoring the $16.91 support as a critical level for potential downside acceleration in the near term.